U.S. drugmaker Eli Lilly and French pharmaceutical company Adocia agree to a $570 million deal to develop a fast-acting insulin. BioChaperone Lispro, is currently in the early stages of clinical testing and will help treat both type one and type two diabetes. If the development and sales milestones are met, Eli Lilly will pay out $280 million and then $240 million as well as the $50 million they will be paying upfront. Insulins are a key revenue generator for Eli Lilly. Shares of Eli Lilly are up 42% for the year. Whalen MacHale reports for TheStreet from New York.